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ABSTRACT 
Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We 
investigated the expression of proteins involved in the DNA damage response (ATM, Chk2), double-strand 
break repair (BRCA1, BLM, WRN, RECQL4, RECQL5, TOPO2A, DNA-PKcs, Ku70/Ku80), nucleotide 
excision repair (ERCC1), base excision repair (XRCC1, pol β, FEN1, PARP1), and immune responses 
(CD8, PD-1, PD-L1, FOXP3) in 1269 breast cancers and validated our findings in an independent estrogen 
receptor (ER)– cohort (n = 279). Patients with tumors that expressed low XRCC1, low ATM, and low 
BRCA1 were not only associated with high numbers of CD8+ tumor-infiltrating lymphocyte (TILs), but 
were also linked to higher grades, high proliferation indexes, presence of dedifferentiated cells, ER– cells 
and poor survival (all P ≤ 0.01). PD-1+ or PD-L1+ breast cancers with low XRCC1 were also linked to an 
aggressive phenotype that was high grade, had high proliferation indexes, contained dedifferentiated cells 
and ER– (all with P values ≤ 0.01) and poor survival (P =  0.00021 and P = 0.00022, for PD-1+ and PD-L1+ 
cancers, respectively) including in an independent ER– validation cohort (P = 0.007 and P = 0.047, 
respectively). We conclude that the interplay between DNA repair, CD8, PD-L1, and PD-1 can promote 
aggressive tumor phenotypes. XRCC1-directed personalization of immune checkpoint inhibitor therapy may 
be feasible and warrants further investigation in breast cancer.   
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INTRODUCTION 
The breast cancer tumor microenvironment includes infiltrating inflammatory cells such as lymphocytes and 
macrophages. CD8+ T-lymphocytes are critical for tumor-specific adaptive immunity (1). We have 
previously investigated the clinicopathological and prognostic significance of tumor-infiltrating CD8+ T 
lymphocytes (TILs) in a large cohort of breast cancers (2). CD8+ TILs were correlated to high tumor grade, 
hormone receptor negative, and basal-like phenotype. High total CD8+ counts were independently associated 
with favorable clinical outcome (2). A recent large study in 12,439 breast cancers has provided confirmatory 
evidence that CD8+ TILs are associated with significant reduction in the relative risk of death in estrogen 
receptor (ER)– as well as in ER+/HER-2+ breast cancers (3).  
Breast cancers with enhanced immunogenicity will be prone to attack by CD8+ T lymphocytes. Impaired 
DNA repair and the associated genomic instability not only leads to increased mutagenicity/carcinogenicity 
but can also increase neoantigen load on tumor cell surface resulting in increased immunogenicity. This 
concept of DNA repair deficiency and enhanced immunogenicity was shown in mismatch repair (MMR)-
deficient colorectal cancers that had a good response to PD-1 blockade (pembrolizumab) therapy compared 
to tumors that are MMR proficient (4, 5).  Whether a similar mechanism can also operate in breast cancers is 
currently unknown. In the current study we profiled proteins involved in the DNA damage response (ATM, 
Chk2), double strand break repair (BRCA1, BLM, WRN, RECQL4, RECQL5, TOPO2A, DNA-PKcs, 
Ku70/Ku80), nucleotide excision repair (ERCC1), base excision repair (XRCC1, pol β, FEN1, PARP1) and 
immune response (CD8, PD-1, PD-L1, FOXP3]) in 1269 breast cancers and validated in an independent ER- 
cohort (n = 279). 
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PATIENTS AND METHODS 
The study was performed in a consecutive series of 1650 patients with primary invasive breast carcinomas 
who were diagnosed between 1986 and 1998 and enrolled into the Nottingham Tenovus Primary Breast 
Carcinoma series. Patient demographics are summarized in Supplementary Table S1. This is a well-
characterized series of patients with long-term follow-up that have been investigated in a wide range of 
biomarker studies (6-14). All patients were treated in a uniform way in a single institution with standard 
surgery (mastectomy or wide local excision), followed by radiotherapy.   Prior to 1989, patients did not 
receive systemic adjuvant treatment (AT). After 1989, AT was scheduled based on prognostic and predictive 
factor status, including Nottingham prognostic index (NPI), estrogen receptor-α (ER-α) status, and 
menopausal status. Patients with NPI scores of < 3.4 (low risk) did not receive AT. In premenopausal 
patients with NPI scores of ≥ 3.4 (high risk), classical cyclophosphamide, methotrexate, and 5-flurouracil 
(CMF) chemotherapy was given; patients with ER-α positive tumors were also offered endocrine therapy. 
Postmenopausal patients with NPI scores of ≥ 3.4 and ER positivity were offered endocrine therapy, 
whereas ER negative patients received classical CMF chemotherapy. Median follow up time was 111 
months (range 1 to 233 months).  Breast cancer–specific survival (BCSS) data was maintained on a 
prospective basis and was defined as the number of months from diagnosis to the occurrence of BC-related 
death. Survival was censored if the patient was still alive at the time of analysis, lost to follow-up, or died 
from other causes. 
We also evaluated an independent series of 279 ER-α negative invasive BCs diagnosed and managed at the 
Nottingham University Hospitals between 1999 and 2007.  All patients were primarily treated with surgery, 
followed by radiotherapy and anthracycline/CMF chemotherapy. The characteristics of this cohort are 
summarized in Supplementary Table S2.  
Tissue Microarrays (TMAs) and immunohistochemistry (IHC): Tumors were arrayed in tissue 
microarrays (TMAs) constructed with 0.6mm cores. The TMAs were immunohistochemically profiled for 
ATM, Chk2, BRCA1, BLM, WRN, RECQL4, RECQL5, TOPO2A, DNA-PKcs, Ku70/Ku80, ERCC 
XRCC1, pol β, FEN1, PARP1, CD8, and FOXP3 expression as previously described (2, 6-15). 
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Supplementary Table S3 summarizes antigens, primary antibodies, clone, source, optimal dilution, scoring 
system and cut-offs used for each DNA repair marker, ER, PR and HER-2 expression.  The specificity of the 
antibodies used is described in our recent publications (2, 6-15).  
IHC protocol: Detailed IHC protocol and evaluation of immune staining is summarized in supplementary 
Table S3. Immunohistochemical staining was performed using the Thermo Scientific Shandon Sequenza 
chamber system (REF: 72110017), in combination with the Novolink Max Polymer Detection System 
(RE7280-K: 1250 tests), and the Leica Bond Primary Antibody Diluent (AR9352), each used according to 
the manufacturer’s instructions (Leica Microsystems).  Leica Autostainer XL machine was used to 
dewax and rehydrate the slides. Pre-treatment antigen retrieval was performed on the TMA sections using 
sodium citrate buffer (pH 6.0) and heated for 20 minutes at 950C in a microwave (Whirlpool JT359 Jet Chef 
1000W). Negative and positive (by omission of the primary antibody and IgG-matched serum) controls were 
included for each marker in each run. The negative control ensured that all the staining was produced from 
the specific interaction between antibody and antigen. HER2 expression was assessed according to the new 
ASCO/CAP guidelines using IHC and fluorescence in situ hybridization (FISH) (16). 
Evaluation of immune staining: Whole field inspection of the core was scored and intensities of nuclear 
staining for DNA repair markers were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate 
staining, 3 = strong staining. The percentage of each category was estimated (0-100%).  H-score (range 0-
300) was calculated by multiplying intensity of staining and percentage staining. The number of CD8+ T 
lymphocytes was counted in each tumor core by using a Nikon Eclipse 80i microscope (Nikon, Tokyo, 
Japan) and an eyepiece graticule. CD8+and FOXP3+ T cells were counted in three locations in each tumor: 
intratumoral compartment (within the tumor cell nests), within the distant stroma (defined as more than one 
tumor cell diameter away from the tumor), and within the adjacent stroma (defined as CD8+ cells within one 
tumor cell diameter of the tumor). The total number of CD8+ T cells was determined by combining the 
counts for these three compartments.   
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Not all cores within the TMA were suitable for IHC assessments as some cores were missing or containing 
inadequate invasive tumor (< 15% of whole core surface area). Tumor marker prognostic studies 
(REMARK) criteria, recommended by McShane et al., (17),  were followed throughout this study.  Ethical 
approval was obtained from the Nottingham Research Ethics Committee (C202313).  
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 21 Chicago, IL). Where 
appropriate, Pearson’s χ2, Fisher’s exact, the student t and one-way ANOVA tests were used. Cumulative 
survival probabilities were estimated using the Kaplan–Meier method, and differences between survival 
rates were tested for significance using the log-rank test. Multivariate analysis for survival was performed 
using the Cox proportional hazard model. The proportional hazards assumption was tested using standard 
log-log plots. Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for each variable. 
All tests were two-sided with a 95% CI and P < 0.05 considered significant. For multiple comparisons, P 
values were adjusted according to the Benjamini-Hochberg method (18). 
8 
 
RESULTS 
Significance of ATM, BRCA1, and XRCC1 in CD8+ TIL-positive breast cancers 
CD8+ T-lymphocytes are critical for tumor-specific adaptive immunity (1). A total of 1269 invasive breast 
carcinomas [ER+ (n = 928), ER– (n = 341), triple negative (n = 219), HER2+/ER– (n = 92), and HER2+/ER+ 
(n = 89)] were suitable for CD8+ TIL assessments; 1032 were positive for CD8+ TILs and 237 cases were 
negative for CD8+ TILs (Fig. 1A1–1A4). 
Low ATM, BRCA1, and XRCC1 expression was associated with poor BCSS in tumors with CD8+ TILs (P 
= 0.006, 0.001, and 0.000011, respectively; Fig. 1A9-A12, B, C, and D), but not in tumors negative for 
CD8+ TILs (P = 0.217, 0.723, and 0.249, respectively; Supplementary Fig. S1A, B, and C).  Expression of 
pol β, ERCC1, RECQL4, RECQL5, BLM, PARP1, FEN1, TOPO2A, Ku70/Ku80, and Chk2 was not 
significantly associated with survival in CD8+ TIL–positive or –negative breast cancers (Supplementary 
Fig. S2A–2T). In tumors positive for CD8+ TILs, WRN did not influence survival (P = 0.332, 
Supplementary Fig. S2U) but in tumors negative for CD8+ TILs, low WRN influenced survival (P = 0.026, 
Supplementary Fig. S2V).  Similarly, in tumors positive for CD8+ TILs, DNA-PKcs did not influence 
survival (P = 0.996, Supplementary Fig. S2W) but in tumors negative for CD8+ TILs, low DNA-PKcs 
influenced poor survival (P = 0.044, Supplementary Fig. S2X).   
To investigate whether low tumor ATM, BRCA1 or XRCC1 expression increased CD8+ TILs counts and 
resulted in an aggressive phenotype, we proceeded to investigate clinicopathological associations.  The 
mean CD8+ TIL counts were significantly higher in tumors with low ATM (P = 0.004), low BRCA1 (P = 
2.4 x 10 -9) and low XRCC1 (P = 0.007; Supplementary Fig. S3). Tumors with low ATM, low BRCA1, or 
low XRCC1 and that contained CD8+ TILs were significantly more likely to manifest aggressive features, 
including high grade, high mitotic index, de-differentiation, ER negativity, and PR negativity (all adjusted P 
values ≤ 0.05; Supplementary Tables S4, S5 and S6).  
Significance of ATM, BRCA1 and XRCC1 in FOXP3+ breast cancers  
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T regulatory cells (Tregs) can inhibit antitumor responses. FOXP3, a member of the forkhead family of 
transcription factors, is restricted to specific population of Tregs (19). In FOXP3+ breast cancers (Fig. 1A5), 
low BRCA1 (P = 0.016) and low XRCC1 (P = 0.000002) expression influenced survival but ATM did not 
(P = 0.536) (Supplementary Fig. S4A-C). On the other hand, in FOXP3 negative breast cancers, low ATM 
influenced poor BCSS (P = 0.001) (Supplementary Fig. S4D) but BRCA1 and XRCC1 amounts did not (P 
= 0.556 and 0.084, respectively) (Supplementary Fig. S4E and F). Low ATM, low BRCA1 or low XRCC1 
and FOXP3+ breast cancers were highly significantly associated with high grade, high risk NPI, high mitotic 
index, pleomorphism, HER-2+, ER– and PR– phenotypes (all adjusted p values <0.0001) (Supplementary 
Tables S7, S8, and S9). The data provides compelling evidence that Tregs infiltration along with tumor 
DNA repair expression can influence breast cancer pathology and outcomes.   
Significance of ATM, BRCA1, and XRCC1 in PD-L1+/PD-1+ breast cancers   
Programmed death ligand-1 (PD-L1) and programmed death-1 (PD-1) are key members of the PD pathway 
involved in immune regulation. The interaction of PD-L1 with PD-1 induces T cell suppression. 
Accordingly the PD-L1/PD-1 pathway has emerged as a key target for immune checkpoint inhibitor therapy 
(20). We investigated ATM, BRCA1, and XRCC1 expression in PD-L1+/PD-1+ or PD-L1–/PD-1– breast 
cancers (Figures 1A6-A8).    
Low XRCC1 expression was associated with poor BCSS in PD-L1+ (tumor cells), PD-L1+ (TILs), and PD-
1+ (TILs) breast cancers (P = 0.00021, 0.007, and 0.00022, respectively; Fig. 1E, F, and G).  ATM and 
BRCA1 amounts did not influence survival in PD-L1+/ or PD-1+ breast cancers (Supplementary Fig. S5A– 
F). In PD-L1– breast cancers, ATM, BRCA1 and XRCC1 did not influence survival (Supplementary Fig. 
S6A–F). In PD-1– breast cancers, low ATM, low BRCA1, and low XRCC1 were associated with poor BCSS 
(Supplementary Fig. S6G–I). 
In PD-L1+ (tumor cells) (Table 1), PD-L1+ (TILs) (Table 2),  or PD-1+ (TILs) (Table 3) breast cancers, low 
XRCC1 amounts were significantly associated with aggressive features including high grade, high risk NPI, 
high mitotic index, pleomorphism, ER negativity and PR negativity (all adjusted P values < 0.001). Taken 
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together, the data provides evidence that low XRCC1 expression was associated with aggressive phenotype 
and poor outcomes in PD-L1+ and PD-1+ breast cancers. We then proceeded to investigate in breast cancers 
subgroups. 
Prognostic significance of ATM, BRCA1, and XRCC1 in ER+ or HER-2+ breast cancers 
In ER+ tumors, although CD8+ TILs alone did not influence survival (Supplementary Fig. S7A– C), low 
BRCA1 (P = 0.002) and low XRCC1 (P <0.0001) were linked to poor BCSS (Supplementary Fig. S8A 
and B). Low ATM expression was not significant (P = 0.080; Supplementary Fig. S8C). 
In PD-1+/PD-L1+ (TILs) or PD-L1+ (tumor cells) ER+ breast cancers that received endocrine therapy, ATM, 
BRCA1, or XRCC1 did not influence survival (unpublished observations). However, XRCC1 expression 
influenced survival in CD8+, PD-1+, or FOXP3+ ER+ breast cancers that received no endocrine therapy (P = 
0.02, 0.038, and 0.026 respectively; Supplementary Fig. S9A–C) but was not significant to PD-L1+ (tumor 
cells) breast cancers (Supplementary Fig. S9D, P = 0.078). 
XRCC1 amounts influenced survival in PD-1+ HER-2+ breast cancers (P = 0.011; Supplementary Fig. 
S10A). ATM and BRCA1 did not associate with survival in CD8+, FOXP3+, or PD-1+ HER-2+ breast 
cancers (unpublished observations). BRCA1 expression was borderline associated with survival in FOXP3+ 
HER-2+ breast cancers (P = 0.05; Supplementary Fig. S10B). ATM and XRCC1 did not associate with 
survival in FOXP3+ HER-2+ breast cancers (unpublished observations).  ATM, BRCA1, or XRCC1 did not 
influence survival in PD-L1+ (TILs) or PD-L1+ (tumor cells) HER2+ breast cancers (unpublished 
observations).  
Prognostic significance of ATM, BRCA1, and XRCC1 in ER– breast cancers 
As expected, CD8+ TILs alone was associated with longer survival in ER– tumors (P = 0.013) 
(Supplementary Fig. S11A) including in patients who received no chemotherapy (P = 0.029) 
(Supplementary Fig. S11B),  but was not significant to patients who received CMF based chemotherapy (P 
= 0.081) (Supplementary Fig. S11C).  In ER– tumors with CD8+ TILs that received CMF chemotherapy, 
low ATM, low BRCA1, or low XRCC1 did not influence survival (unpublished observations).  
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In PD-L1+ (TILs) ER– breast cancers that received no chemotherapy, BRCA1 amounts influenced survival 
(Supplementary Fig. S12), but ATM and XRCC1 did not (unpublished observations). ATM, BRCA1, or 
XRCC1 did not influence survival in FOXP3+, PD-1+, or PD-L1+ (tumor cells) ER– breast cancers that 
received no chemotherapy (unpublished observations). Similarly, ATM, BRCA1, or XRCC1 did not 
influence survival in FOXP3+, PD-1+, PD-L1+ (TILs) or PD-L1+ (tumor cells) ER– breast cancers that 
received CMF chemotherapy (unpublished observations).  
We then proceeded to investigate an independent ER– cohort that received modern anthracycline based 
chemotherapy. Low XRCC1 expression was associated with poor survival in PD-L1+ (TILs) and PD-1+ 
(TILs) ER– breast cancers (P = 0.047 and P = 0.007 respectively; Fig. 1I, 1J). Low XRCC1 expression was 
not significant (P = 0.089) to PD-L1+ (tumor cells) ER– breast cancers (Fig. 1H). ATM or BRCA1 did not 
influence survival in this cohort (unpublished observations).  
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DISCUSSION 
The presence of TILs is a marker for a good prognosis (1-3, 21, 22) and predicts a favorable response to 
neoadjuvant chemotherapy in breast cancer (23). Although the biological mechanisms are poorly 
understood, immune effector cells, their cytokine secretions, or cancer cell immunogenicity may influence 
biology and antitumor response in breast cancer. In addition, chemotherapy-induced Treg depletion, could 
also allow pre-existing immune-effector cells to operate effectively and induce antitumor responses (1).  
CD8+ TILs can be a good marker of response to neoadjuvant chemotherapy, providing evidence that specific 
immune-effector cells could be essential (23). Another possibility is that the immunogenicity of tumor cells 
themselves could influence immune-effector cell anticancer activity. Tumor cells with abundant surface 
neoantigens will be prone to immune-attack compared to tumor cells with low neoantigen load. Emerging 
data provide evidence that tumors with many somatic mutations accumulate neoantigens and are highly 
immunogenic (5). A key determinant of mutation load is the DNA repair capacity in cancer cells. DNA 
repair–deficient cancers have increased genomic instability, leading to a ‘mutator phenotype’ characterized 
by the accumulation of mutations. For example, MMR-deficient colorectal cancers not only have 10 to 100 
times more somatic mutations compared MMR-proficient colorectal tumors, but also have prominent 
lymphocytic infiltration (5).   A pivotal phase II study of PD-1 blockade by pembrolizumab provided the 
first compelling evidence that MMR-deficient colorectal cancer are more responsive to immune checkpoint 
inhibitor therapy compared to MMR-proficient tumors (5). In breast cancers, however, MMR deficiency is 
rare (24), suggesting that impairment of other DNA repair factors may influence prognosis in tumors with 
immune cell infiltration.  
In the current study, a key initial observation was that low amounts of ATM, BRCA1, and XRCC1 increased 
CD8+ TIL infiltration, and was associated with aggressive pathology, leading to poor patient survival. Germ-
line mutations in ATM or BRCA1 predispose to hereditary breast cancers. In sporadic breast cancers, 
epigenetic silencing of the BRCA1 promoter has been reported in up to 11%–14% of tumors. About 25% of 
breast cancers may have a dysfunctional BRCA pathway in which they do not harbor germ-line BRCA 
mutations, but display similar phenotypes, including HR deficiency. XRCC1 deficiency delays SSB 
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rejoining, induces mutations, and results in elevated numbers of sister chromatid exchanges, a hallmark of 
genomic instability. Polymorphism in XRCC1 gene may increase the risk of cancer.  We have previously 
shown that having little ATM or XRCC1 protein in somatic tumors is associated with aggressive breast 
cancers and poor survival (6, 14).  We therefore speculate that reduced protein expression of ATM, BRCA1, 
or XRCC1 could lead to a ‘mutator phenotype’, increase immunogenicity, promote CD8+ TILs, and 
influence tumor biology and outcome.  However, a limitation to the current study is that we have not directly 
shown an increased mutational load in ATM/BRCA1/XRCC1-deficient tumors compared to 
ATM/BRCA1/XRCC1-proficient tumors. This will be an important area for future investigation.  Given the 
essential role of Tregs in attenuating immune response in the tumor microenvironment (19), we also 
investigated the expression of ATM, BRCA1, and XRCC1 in FOXP3+ breast cancers. We observed highly 
significant associations with aggressive phenotypes and outcome implying that ATM-, BRCA1-, and 
XRCC1-deficient breast cancers elicit complex immune responses including cytotoxic T cell, as well as 
Treg, infiltration.  
The PD-1 pathway is critical for immune regulation. PD-L1/PD-1 interaction induces T-cell repression. PD-
L1/PD-1–targeted immune checkpoint inhibitor therapy is an exciting approach in cancers (20). Although 
durable responses have been seen in PD-L1+ non-small cell lung cancer (25), not all patients respond to 
pembrolizumab (a humanized monoclonal antibody to PD-1).  Therefore, evaluation of potential biomarkers 
that could allow personalization of PD-L1+ solid tumors is a high priority.  We provide clinical evidence that 
XRCC1 expression can stratify patients into distinct prognostic groups in PD-L1+ and PD-1+ breast cancers, 
including in ER negative breast cancers. In addition, low XRCC1 expression also promoted aggressive PD-
L1+ and PD-1+ breast cancer phenotypes, implying potential roles in breast cancer biology. Although none 
of the patients investigated in the current study received anti PD-1 therapy, our data taken together, would 
suggest that XRCC1 could aid in the personalization of anti PD-1 therapy that are currently under 
investigation in PD-L1+ breast cancers.  Prospective evaluation of this possibility is warranted in the context 
of clinical trials. 
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In conclusion, we provide clinical evidence that the interplay between DNA repair, CD8, PD-L1, and PD-1 
can promote aggressive tumor phenotypes. XRCC1-directed personalization of immune checkpoint inhibitor 
therapy may be feasible in breast cancer.   
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FIGURE LEGENDS 
Figure 1:  A. Immunohistochemical expression of CD8, FOXP3, PD-1, PD-L1, ATM, BRCA1, and XRCC1 
in breast cancers (all images are at 20x magnification). A1) Invasive carcinoma, infiltrate with minimal 
lymphocytic infiltrate. A2) Invasive carcinoma with extensive CD8 negative lymphocytic infiltrate. A3)  
Invasive carcinoma showing CD8 positive intra-tumoral lymphocytic infiltrate. A4)  Invasive carcinoma 
with extensive CD8 positive peri-tumoral lymphocytic infiltrate. A5) FOXP3 positive (TILs staining) 
invasive carcinoma. A6) PD-1 positive (TILs staining) invasive carcinoma. A7) PD-L1 positive (Tumor cell 
staining) invasive carcinoma. A8) PD-L1 positive (TILs staining) invasive carcinoma.   A9) ATM negative 
invasive carcinoma. A10) ATM positive invasive carcinoma. A11) BRCA1 positive invasive carcinoma.  
A12)  XRCC1 positive invasive carcinoma. B. Prognostic significance of ATM expression in CD8+ TILs 
positive breast cancers (Kaplan-Meier survival curves is shown here). C. Prognostic significance of BRCA1 
expression in CD8+ TILs positive breast cancers. D. Prognostic significance of XRCC1 expression in CD8+ 
TILs positive breast cancers. E. Prognostic significance of XRCC1 expression in PD-L1 positive (tumor 
cells) breast cancers. F. Prognostic significance of XRCC1 expression in PD-L1 positive (TILs) breast 
cancers. G. Prognostic significance of XRCC1 expression in PD-1 positive (TILs) breast cancers. H. 
Prognostic significance of XRCC1 expression in PD-L1 positive (tumor cells) ER negative breast cancers. I. 
Prognostic significance of XRCC1 expression in PD-L1 positive (TILs) ER negative breast cancers. J. 
Prognostic significance of XRCC1 expression in PD-1 positive (TILs) ER negative breast cancers. 
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Table 1: Clinicopathological significance of XRCC1 expression in PD-L1 positive (tumor cells) and PDLI negative breast 
cancers. 
 
 
 
 
PD-L1 (tumor cells) and XRCC1 expression 
 
 
P value 
 
 
 
P value 
(adjusted) XRCC1+ 
/PD-L1+ 
 
XRCC1+ 
/PD-L1– 
 
XRCC1– 
/PD-L1+ 
 
XRCC1– 
/PD-L1– 
 
A) Pathological    Parameters 
Tumor Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
39 (69.6%) 
258 (66.7%) 
208 (67.1%) 
8 (72.7%) 
 
7 (12.5%) 
76 (19.6%) 
35 (11.3%) 
1 (9.1%) 
 
9 (16.1%) 
37 (9.6%) 
57 (18.4%) 
2 (18.2%) 
 
1 (1.8%) 
16 (4.1%) 
10 (3.2%) 
0 (0.0%) 
 
 
0.018 
 
 
0.022 
Tumor Stage                                 
1 
2 
3 
 
297 (65.4%0 
167 (69.0%) 
52 (74.3%) 
 
87 (19.2%) 
23 (9.5%) 
9 (12.9%) 
 
50 (11.0%) 
47 (19.4%) 
8 (11.4%) 
 
20 (4.4%) 
5 (2.1%) 
1 (1.4%) 
 
 
0.000966 
 
 
0.00015 
Tumor Grade                              
 G1 
 G2 
 G3 
 
80 (71.4%) 
183 (71.5%) 
251 (63.2%0 
 
21 (18.8%) 
50 (19.5%) 
48 (12.1%) 
 
9 (8.0%) 
14 (5.5%) 
82 (20.7%) 
 
2 (1.8%) 
9 (3.5%) 
16 (4.0%) 
 
 
7.45 X 10-7 
 
 
<0.00001 
NPI                              
 ≤ 3.4 
 >3.4 
 
145 (70.0%) 
338 (65.3%) 
 
46 (22.2%) 
70 (13.5%) 
 
10 (4.8%) 
90 (17.4%) 
 
6 (2.9%) 
20 (3.9%) 
 
0.000017 
 
<0.00001 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
172 (72.6%) 
102 (67.5%) 
231 (64.9%) 
 
45 (19.0%) 
23 (15.2%) 
40 (11.2%) 
 
16 (6.8%) 
17 (11.3%) 
71 (19.9%) 
 
4 (1.7%) 
9 (6.0%) 
14 (3.9%) 
 
 
0.000029 
 
 
0.0001 
Tubule Formation                          
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
31 (79.5%) 
175 (72.9%) 
299 (64.3%) 
 
4 (10.3%) 
31 (12.9%) 
73 (15.7%) 
 
4 (10.3%) 
26 (10.8%) 
74 (15.9%) 
 
0 (0.0%) 
8 (3.3%) 
19 (4.1%) 
 
0.175 
 
1.925 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
7 (63.6%) 
203 (70.7%) 
294 (66.1%) 
 
3 (27.3%) 
54 (18.8%) 
51 (11.5%) 
 
1 (9.1%) 
19 (6.6%) 
84 (18.9%) 
 
0 (0.0%) 
11 (3.8%) 
16 (3.6%) 
 
 
0.000108 
 
 
0.0002 
Tumor Type                
IDC-NST 
Tubular  
Medullary  
ILC 
Others 
Mixed NST & Lobular/special 
type 
 
313 (66.5%) 
103 (74.1%) 
9 (45.0%) 
48 (67.6%) 
4 (44.4%) 
26 (61.9%) 
 
65 (13.8%) 
18 (12.9%) 
2 (10.0%) 
19 (26.8%) 
3 (33.3%) 
10 (23.8%) 
 
76 (16.1%) 
14 (10.0%) 
7 (35.0%) 
3 (4.2%) 
2 (22.2%) 
3 (7.1%) 
 
17 (3.6%) 
4 (2.9%) 
2 (10.0%) 
1 (1.4%) 
0 (0.0%) 
3 (7.1%) 
 
 
 
0.002 
 
 
 
0.0028 
Her2 overexpression                     
No 
Yes 
 
 
449 (68.1%) 
64 (64.0%) 
 
 
100 (15.2%) 
17 (17.0%) 
 
 
86 (13.1%) 
16 (16.0%) 
 
 
24 (3.6%) 
3 (3.0%) 
 
 
 
0.022 
 
 
0.0242 
ER status               
Negative 
Positive 
 
117 (58.8%) 
391 (71.2%) 
 
23 (11.6%) 
90 (16.4%) 
 
46 (23.1%) 
55 (10.0%) 
 
13 (6.5%) 
13 (2.4%) 
 
6.9 X 10-7 
 
<0.00001 
PR                                   
Negative 
 
185 (60.3%) 
 
41 (13.4%) 
 
64 (20.8%) 
 
17 (5.5%) 
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Positive 
 
316 (73.1%) 69 (16.0%) 
 
39 (9.0%) 
 
8 (1.9%) 0.000001 <0.00001 
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              Table 2: Clinicopathological significance of XRCC1 expression in PD-L1 positive (TILs) and PD-L1 negative breast cancers. 
  
PD-L1 (TILs) and XRCC1 expression 
 
 
P value 
 
P value 
(adjusted) 
 XRCC1– 
/PD-L1– 
 
XRCC1+ 
/PD-L1– 
 
XRCC1– 
/PD-L1+ 
 
XRCC1+ 
/PD-L1+ 
 
A) Pathological    Parameters 
Tumor Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
4(7.4%) 
25(7.3%) 
23(8.4%) 
1  (9.1%) 
 
21 (38.9%) 
160(46.5%) 
89  (32.5%) 
3   (27.3%) 
 
6 (11.1%) 
23(6.7%) 
37(13.5%) 
1  (9.1%) 
 
23 (42.6%) 
136(39.5%) 
125(45.6%) 
6    (54.5%) 
 
 
0.044 
 
 
0.0484 
Tumor Stage                           
1 
2 
3 
 
31(7.8%) 
20(9.1%) 
1  (1.5%) 
 
172(43.1%) 
75(34.1%) 
27(40.9%) 
 
32(8.0%) 
29 (13.2%) 
6   (9.1%) 
 
164(41.1%) 
96  (43.6%) 
32 (48.5%) 
 
0.075 
 
0.825 
Tumor Grade                          
 G1 
 G2 
 G3 
 
7 (7.0%) 
12(5.3%) 
34 (9.5%) 
 
51 (51%) 
125(55.6%) 
98 (27.3%) 
 
4 (4%) 
6 (2.7%) 
57(15.9%) 
 
38 (38%) 
82 (36.4%) 
170(47.4%) 
 
1.57x10-12 
 
<0.00001 
NPI                              
 ≤ 3.4 
 >3.4 
 
10 (5.4%) 
41 (8.8%) 
 
106(57.6%) 
159(34.3%) 
 
4 (2.2%) 
59 (12.7%) 
 
64 (34.8%) 
205(44.2%) 
 
3.8x10-8 
 
<0.00001 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
12 (5.5%) 
13 (10.1%) 
28 (8.7%) 
 
112(51.6%) 
57  (44.2%) 
94  (29.1%) 
 
8 (3.7%) 
7 (5.4%) 
52(16.1%) 
 
85 (39.2%) 
52 (40.3%) 
149(46.1%) 
 
4.1x10-8 
 
<0.00001 
Tubule Formation                  
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
3 (8.6%) 
13(6.1%) 
37 (8.8%) 
 
17 (48.6%) 
102(47.9%) 
144(34.2%) 
 
1 (2.9%) 
16(7.5%) 
50 (11.9%) 
 
14 (40%) 
82 (38.5%) 
190(45.1%) 
 
0.021 
 
0.0257 
Pleomorphism                         
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
1 (10.0%) 
18 (7.2%) 
34 (8.4%) 
 
4 (40.0%) 
136(54.2%) 
123(30.2%) 
 
0 (0%) 
8 (3.2%) 
59(14.5%) 
 
5 (50.0%) 
89 (35.5%) 
191(46.9%) 
 
8.5x10-9 
 
<0.00001 
Tumor Type                
IDC-NST 
Tubular  
Medullary  
ILC 
Others 
Mixed NST & 
Lobular/special type 
 
33 (7.8%) 
9   (7.4%) 
3   (15.8%) 
3   (4.7%) 
1   (20.0%) 
4   (10.0%) 
 
132(31.4%) 
69  (56.6%) 
2   (10.5%) 
39 (60.9%) 
2   (40.0%) 
24 (60.0%) 
 
51 (12.1%) 
7   (5.7%) 
6   (31.6%) 
1   (1.6%) 
0   (0%) 
2   (5.0%) 
 
205(48.7%) 
37  (30.3%) 
8   (42.1%) 
21 (32.8%) 
2   (40.0%) 
10 (25.0%) 
 
1.9x10-8 
 
<0.00001 
Her2 overexpression               
No 
Yes 
 
 
44 (7.5%) 
10 (11.0%) 
 
248(42.2%) 
22  (24.2%) 
 
55 (9.4%) 
9   (9.9%) 
 
241(41.0%) 
50  (54.9%) 
 
0.01 
 
0.0138 
ER status               
ER – 
ER + 
 
 
19 (10.5%) 
31 (6.4%) 
 
34 (18.8%) 
232(47.5%) 
 
35(19.3%) 
31 (6.4%) 
 
93 (51.4%) 
194(39.8%) 
 
2.4x10-12 
 
<0.00001 
PR                                   
Negative 
Positive 
 
 
29 (10.7%) 
22 (5.7%) 
 
78 (28.7%) 
185(47.7%) 
 
43 (15.8%) 
22 (5.7%) 
 
122(44.9%) 
159(41.0%) 
 
4.8x10-8 
 
<0.00001 
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Table 3: Clinicopathological significance of XRCC1 expression in PD-1 positive (TILs) and PD1 negative breast cancers. 
 
 
 
 
  
PD-1 and XRCC1 expression 
 
 
P value 
 
 
P value 
(Adjusted) 
 XRCC1– 
/PD-1– 
 
XRCC1+ 
/PD-1– 
 
XRCC1– 
/PD-1+ 
 
XRCC1+ 
/PD-1+ 
A) Pathological    Parameters 
Tumor Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
4(6.2%) 
19(4.3%) 
25(7.1%) 
1(7.7%)  
 
32(49.2%) 
210(47.9%) 
129(36.9%) 
4   (30.8%) 
 
7 (10.8%) 
41(9.4%) 
48(13.7%) 
2 (15.4%) 
 
22(33.8%) 
168(38.4%) 
148(42.3%) 
6 (46.2%) 
 
0.111 
 
0.137 
Tumor Stage                             
1 
2 
3 
 
26(5.2%) 
19(6.6%) 
4   (5.2%) 
 
232(46.2%) 
118(40.8%) 
27(35.1%) 
 
49(9.8%) 
40(13.8%) 
8  (10.4%) 
 
195(38.8%) 
112(38.8%) 
38 (49.4%) 
 
0.239 
 
2.64 
Tumor Grade                            
 G1 
 G2 
 G3 
 
5 (4.0%) 
11(4.1%) 
33(7.0%) 
 
83(66.9%) 
152(56.1%) 
141(29.9%) 
 
6(4.8%) 
13(4.8%) 
79(16.7%) 
 
30(24.2%) 
95(35.1%) 
219(46.4%) 
 
1X10-13 
 
<0.00001 
NPI                              
 ≤ 3.4 
 >3.4 
 
8(3.6%) 
39(6.4%) 
 
139(62.6%) 
224(37.0%) 
 
 
9 (4.1%) 
85(14%) 
 
66(29.7%) 
257(42.5%) 
 
2.63X10-10 
 
<0.00001 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
7(2.7%) 
15(9.1%) 
27(6.4%) 
 
155(59.6%) 
76 (46.1%) 
132(31.4%) 
 
14(5.4%) 
13(7.9%) 
70(16.7%) 
 
84(32.3%) 
61(37.0%) 
191(45.5) 
 
3.7X10-12 
 
<0.00001 
Tubule Formation                    
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
2(4.7%) 
20(7.4%) 
27(5.1%) 
 
30(69.8%) 
139(51.5%) 
194(36.5%) 
 
3 (7.0%) 
17 (6.3%) 
77 (14.5%) 
 
8 (18.6%) 
94 (34.8%) 
234 (44%) 
 
0.000001 
 
<0.00001 
Pleomorphism                           
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
1(8.3%) 
15(4.9%) 
33(6.3%) 
 
7 (58.3%) 
195 (63.5%) 
160 (30.5%) 
 
0 (0%) 
15 (4.9%) 
82 (15.6%) 
 
4 (33.3%) 
82 (26.7%) 
250 (47.6) 
 
1 X10-13 
 
<0.00001 
Tumor Type                
IDC-NST 
Tubular  
Medullary  
ILC 
Others 
Mixed NST & 
Lobular/special type 
 
35(6.4%) 
8 (5.2%) 
1(4.3%) 
2(2.6%) 
0 (0%) 
3 (6.5%) 
 
200(36.5%) 
93 (60.8%) 
2   (8.7%) 
49 (62.8%) 
6   (66.7%) 
19  (41.3%) 
 
71(13.0%) 
9  (5.9%) 
8  (34.8%) 
3  (3.8%) 
1  (11.1%) 
6  (13.0%) 
 
 
242(44.2) 
43(28.1%) 
12(52.2%) 
24(30.8%) 
2 (22.2%) 
18(39.1%) 
 
3.3X10-8 
 
<0.00001 
Her2 overexpression                
No 
Yes 
 
 
40(5.4%) 
9 (7.1%) 
 
328(44.5%) 
42 (33.3%) 
 
80(10.9%) 
18 (14.3%) 
 
289(39.2) 
57(45.2%) 
 
0.123 
 
0.1353 
ER status               
Negative 
Positive 
 
18(7.6%) 
28(4.6%) 
 
60(25.4%) 
308(50.1%) 
 
49(20.8%) 
46(7.5%) 
 
109(46.2) 
233(37.9) 
2.87X10-12 
 
<0.00001 
PR                                   
Negative 
Positive 
 
 
26(7.1%) 
19(4%) 
 
124(33.8%) 
236(50.2%) 
 
 
67(18.3%) 
31(6.6%) 
 
150(40.9) 
184(39.1) 
 
8.1X10-9 
 
<0.00001 

Supplementary Table S1:  Clinicopathological characteristics of Nottingham Tenovus series 
 
Variable n* Cases          (%) 
Menopausal status 1650  
Pre-menopausal  612          (37.0) 
postmenopausal  1038        (63.0) 
Tumour Grade (NGS) 1650  
G1   306          (18.5) 
G2  531          (32.2) 
G3   813          (49.3) 
Lymph node stage 1650  
Negative   1056         (64.0) 
Positive (1-3 nodes)  486          (29.5) 
Positive (>3 nodes)  108           (6.5) 
Tumour size (cm) 1650  
T1 a + b (≤1.0)  187         (11.0) 
T1 c (>1.0 -2.0)  868         (53.0) 
T2 (>2.0-5)  579      (35.0) 
T3 (>5)  16         (1.0) 
Tumour type 1650  
IDC-NST  941         (57) 
Tubular   349         (21) 
ILC  160        (10) 
Medullary (typical/atypical)  41          (2.5) 
Others  159        (9.5) 
NPI subgroups 1650  
Excellent PG(2.08-2.40) Low risk 207         (12.5) 
Good PG(2.42-3.40) 331          (20.1) 
Moderate I PG(3.42 to 4.4) High risk 488         (29.6) 
Moderate II PG(4.42 to 5.4) 395         (23.9) 
Poor PG(5.42 to 6.4) 170         (10.3) 
Very poor PG(6.5–6.8) 59         (3.6) 
Survival at 20 years 1650  
Alive and well  1055         (64.0) 
Dead from disease  468          (28.4) 
Dead from other causes  127         (7.6) 
Adjuvant systemic therapy (AT)   
No AT   665         (42.0) 
Hormone therapy (HT)  642         (41.0) 
Chemotherapy (CMF)  307         (20.0) 
Hormone + chemotherapy  46         (3.0) 
* Number of cases for which data were available. 
NPI; Nottingham prognostic index, PG; prognostic group 
 
Supplemental Table S2: Clinicopathological characteristics of ER- cohort 
Variable  Cases          (%) 
Menopausal status 279  
Pre-menopausal  119      (43.6) 
postmenopausal  154      (56.4) 
Tumour Grade (NGS) 279  
G1     1         (0.4) 
G2    26        (9.5) 
G3  248        (90.2) 
Tumour size (cm) 279  
≤2.0   140        (52.6) 
>2.0  126       (47.4) 
Mitotic index 279  
M1  21 (7.5) 
M2  47(16.8) 
M3  274 (98.9) 
Tubule formation 279  
1  1 (0.4) 
2  36 (15.0) 
3  240 (86.6) 
Pleomorphism 279  
1  0 (0) 
2  3 (1.1) 
3  274(98.9) 
Her-2 status 279  
Positive  28 (10) 
Negative  251 (90) 
NPI 279  
Good (≤ 3.4)  15 (5.5) 
Moderate (3.41-5.4)  194 (71.1) 
Poor (>5.4)  64 (23.4) 
NPI; Nottingham prognostic index, PG; prognostic group 
 
  
Supplementary Table S3: Antigens, primary antibodies, clone, source, optimal dilution and scoring system 
used for each immunohistochemical marker 
Antigen Antibody Clone Source Antigen Retrieval 
Dilution /  
Incubatio
n Time 
Distribution Scoring system Cut-offs 
BRCA1 BRCA1 MS110 Calbiochem Citrate pH6 1:100 60 min Nuclear 
% of positive 
cells 
<25% (negative) 
 
ATM 
Rabbit 
MAb anti-
ATM 
Y170 Abcam Citrate pH6 1:100 18 hours Nuclear 
% of positive 
cells 
<25% (negative) 
 
 
XRCC1 
 
Mouse 
MAb Anti-
XRCC1 
 
33-2-5 
 
Thermo-
scientific 
 
Citrate pH6 
 
1:200 
20 min 
 
Nuclear 
 
% of positive 
cells 
 
≥10% (positive) 
Pol β Rabbit anti-polβ Ab26343 Abcam Citrate pH6 
1:200 
60 min Nuclear H- Score 
≥100 
(Median H-score, 
positive) 
BLM Rabbit anti BLM Polyclonal 
Novus-
Biologicals 
Citrate pH6 
 
1:100 
18 Hours 
Nuclear 
 H- Score 
≥50 
(Median H-score, 
positive) 
WRN Rabbit Anti-WRN Polyclonal 
Novus 
Biologicals Citrate pH6 
1:100 
Overnight 
(18h) 
Nuclear 
 H-score 
Nuclear 
≥116(Median H-
score High) 
 
RECQL4 Rabbit Anti RECQL4 Polyclonal 
Novus 
Biologicals Citrate pH6 
1:1000 
60 min 
Nuclear 
 H-score 
Nuclear ≥215 
(Median H-score 
High) 
 
Ku70/ 
Ku80 
Mouse Anti-
Ku70/Ku80 
Monoclona
l Abcam Citrate pH6 
1:2500 
60 min Nuclear H- Score 
>90 
(X-tile cut-off, 
positive) 
CHK2 Rabbit Anti CHK2 Polyclonal Abcam Citrate pH6 
1:100 
60 min Nuclear H- Score 
≥100 
(Median H-score, 
positive) 
PARP1 Mouse MAb Anti-PARP1 7D3-6 
BD 
pharmingen Citrate pH6 1:1000 Nuclear 
% of positive 
cells ≥10% (positive) 
 
TOP2A 
 
Mouse MAb 
 
 
KiS1 
 
Dako-
Cytomation 
 
Citrate pH6 
 
 
1:150 
60 min 
 
Nuclear 
 
 
% of positive 
cells 
 
>25% (positive) 
FEN1 Rabbit anti-FEN1 polyclonal 
Novus 
Biologicals Citrate pH6 
1:200 
60 min Nuclear   H-score >100 (positive) 
DNA-PKcs Mouse MAb Anti- 3H6 Abcam Citrate pH6 
1:1000 
20 min Nuclear H-score 
>260 ((Mean H-
score, positive) 
ER 
Mouse 
MAb anti-
ER-α 
SP1 Dako-Cytomation Citrate pH6 
1:150 
30 min Nuclear Allred score ≥3 (positive) 
ER 
Mouse 
MAb anti-
ER-α 
EP1 Dako-Cytomation Citrate pH6 
1:80 
30 min Nuclear 
% positive 
cells ≥1% positive 
PR 
Mouse 
MAb anti-
PR 
PgR636 Dako-Cytomation Citrate pH6 
1:125 
30 min Nuclear 
% positive 
cells ≥1% positive 
HER2 
Rabbit 
antihuman 
c-erbB2 
polyclonal Dako-Cytomation None 
1:400 
60 min Membrane See text See text 
CD8 
Mouse 
MAb Anti-
CD8 
1A5 Vector Laboratories Citrate pH6 
1:50 
20 min Membrane See text See text 
FOXP3 
Mouse 
MAb Anti-
FOXP3 
236A/E7 Abcam Citrate pH6 1:100 60 min Stroma 
positive cell 
counts ≥3 positive 
PD-1 
Mouse 
MAb Anti-
PD-1 
EH33 
Cell 
Signalling 
Technology 
Citrate pH6 1:75 24 hours Stroma 
% positive 
cells ≥5% positive 
PD-L1 
Rabbit 
MAb Anti-
PD-L1 
E1L3N 
Cell 
Signalling 
Technology 
Epitope 
retrieval 
solution 2, 
pH9, 95°C, 
45 min 
1:25 
24 hours 
Membrane 
Cytoplasm 
Stroma 
% positive in 
tumour 
% positive 
cells in stroma 
≥1% positive 
All sections were pre-treated with microwave antigen retrieval using 0.1% citrate buffer (pH 6) except for HER2 
(no pre-treatment).   
 
 
 
Supplementary Table S4: Clinicopathological significance of ATM expression in CD8+ TILs positive and CD8+ TILs negative 
breast cancer  
  
 
 
 
CD8 and ATM expression 
 
 
 
P- value 
 
 
 
*P -Value 
(Adjusted) ATM+ 
/CD8+ 
 
ATM+ 
/CD8- 
 
ATM- 
/CD8+ 
 
ATM- 
/CD8- 
 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
30 (34.9%) 
165(38.3%) 
91(32.6%) 
3  (21.4%) 
 
5  (5.8%) 
51(11.8%) 
27(9.7%) 
2(14.3%) 
 
41  (47.7%) 
176(40.8) 
141(50.5) 
8   (57.1%) 
 
10 (11.6) 
39(9.0%) 
20 (1.2%) 
1  (7.1%) 
 
0.268 
 
0.2924 
 
Tumour Stage                              
1 
2 
3 
 
191(37.3%) 
77 (32.8%) 
21(33.3%) 
 
59(11.5%) 
25(10.6%) 
2  (3.2%) 
 
214(41.8%) 
114(48.5%) 
38  (60.3%) 
 
48 (9.4%) 
19(8.1%) 
2  (3.2%) 
 
0.054 
 
0.0810 
 
Tumour Grade                            
 G1 
 G2 
 G3 
 
57  (46.0%) 
100(38.3%) 
132(31.0%) 
 
20(16.1%) 
26(10.0%) 
40(9.4%) 
 
40  (32.3) 
110(42.1) 
216(50.7) 
 
7  (5.6%) 
25(9.6%) 
38(8.9%) 
 
0.002 
 
0.0080 
 
NPI                              
 ≤ 3.4 
 >3.4 
 
100(41.7%) 
178(33.1%) 
 
30(12.5%) 
53(9.9%) 
 
90(37.5%) 
258(48.0%) 
 
20(8.3%) 
49(9.1%) 
 
0.034 
 
0.0680 
 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
116(43.8%) 
54  (36.5%) 
116(30.2%) 
 
28(10.6%) 
16(10.8%) 
37(9.6%) 
 
104(39.2%) 
62  (41.9%) 
195(50.8%) 
 
17(6.4%) 
16(10.8%) 
36(9.4%) 
 
0.014 
 
0.0336 
 
Tubule Formation                       
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
12(27.3%) 
111(43.5%) 
163(32.7%) 
 
8(18.2%) 
31(12.2%) 
42(8.4%) 
 
19(43.2%) 
88(34.5%) 
254(51.0%) 
 
5(11.4%) 
25(9.8%) 
39(7.8%) 
 
0.001 
 
0.0120 
 
Pleomorphism                             
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
6    (35.3%) 
112(38.2%) 
167(34.5%) 
 
 
3  (17.6%) 
39(13.3%) 
38(7.9%) 
 
6   (35.3%) 
116(39.6%) 
238(49.2%) 
 
2(11.8%) 
26(8.9%) 
41(8.5%) 
 
0.077 
 
0.1027 
 
Tumour Type                
IDC-NST 
Tubular  
Medullary 
ILC 
Others 
Mixed NST &lobular/ special 
type               
 
 
165 (33.8%) 
70   (42.9%) 
10   (34.5%) 
23   (33.8%) 
2     (22.2%) 
16   (37.2%) 
 
48  (9.8%) 
24  (14.7%) 
1    (3.4%) 
4    (5.9%) 
1    (11.1%) 
6    (14.0%) 
 
236 (48.4%) 
56   (34.4%) 
17   (58.6%) 
35   (51.5%) 
5     (55.6%) 
13   (30.2%) 
 
39  (8.0%) 
13   (8.0) 
1   (3.4%) 
6   (8.8%) 
1   (11.1%) 
8   (18.6%) 
 
 
0.045 
 
 
 
0.0836 
 
 
 
HER-2 overexpression                
No 
Yes 
 
243(35.8%) 
41   (34.2%) 
 
 
76 (11.2%) 
9   (7.5%) 
 
300(44.2%) 
61   (50.8%) 
 
60(8.8%) 
9  (7.5%) 
 
0.459 
 
0.9670 
 
ER               
Negative 
Positive 
 
6.6  (29.6%) 
220 (38.0%) 
 
15  (6.7%) 
71  (12.3%) 
 
121(54.3%) 
242(41.8%) 
 
21(9.4%) 
46(7.9%) 
 
0.003 
 
0.0098 
 
PR                                   
Negative 
Positive 
 
104(31.4%) 
175(38.5%) 
 
23(6.9%) 
62(13.6%) 
 
172(52.0%) 
180(39.6%) 
 
32(9.7%) 
38(8.4%) 
 
0.001 
 
0.0130 
 
Supplementary Table S5: Clinicopathological significance of BRCA1 expression in CD8 positive and CD8 negative breast 
cancer  
 
 
 
 
 
 
 
 
 
 
 
 
P- value 
 
 
 
*P -Value 
(Adjusted) BRCA1+ /CD8+ 
 
BRCA1+ 
/CD8- 
 
BRCA1- 
/CD8+ 
 
BRCA1- 
/CD8- 
 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
79 (77.5%) 
363(68.6%) 
278(68.3%) 
10   (50%) 
 
15 (14.7%) 
86(16.3%) 
51 (12.5%) 
3   (15%) 
 
6  (5.9%) 
64 (12.1%) 
70(17.2%) 
6   (30%) 
 
2  (2.0%) 
16(3.0%) 
8  (2.0%) 
1  (5.0%) 
 
0.26 
 
0.624 
 
Tumour Stage                              
1 
2 
3 
 
418(65.3%) 
245(74.7%) 
67  (73.6%) 
 
107(16.7%) 
41  (12.5%) 
8    (8.8%) 
 
95(14.8%) 
36(11.0%) 
15(16.5%) 
 
20(3.1%) 
6 (1.85%) 
1  (1.1%) 
 
0.40 
 
0.8 
 
Tumour Grade                            
 G1 
 G2 
 G3 
 
112(68.7%) 
263(78.0%) 
355(63.5%) 
 
33 (20.2%) 
53 (15.7%) 
70 (12.5%) 
 
10 (6.1%) 
18  (5.3%) 
118(21.1%) 
 
8 (4.9%) 
3 (0.9%) 
16(2.9%) 
 
3.5x10-12 
 
p<0.0001 
NPI                              
 ≤ 3.4 
 >3.4 
 
218(72.7%) 
474(66.9%) 
 
58 (18.7%) 
94  (13.3%) 
 
18   (6.0%) 
121 (17.1%) 
 
8  (2.7%) 
19 (2.7%) 
 
0.000026 
 
0.0003 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
260 (76.9%) 
142 (73.2%) 
317 (63.4%) 
 
56 (16.6%) 
29 (14.9%) 
62 (12.4%) 
 
17 (5.0%) 
19 (9.8%) 
106(21.2%) 
 
5  (1.5%) 
4  (2.1%) 
15(3.0%) 
 
2.4x10-9 
 
p<0.0001 
Tubule Formation                       
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
36 (64.3%) 
231(70.6%) 
452(69.2%) 
 
14(25.0%) 
56(17.1%) 
77(11.9%) 
 
2   (3.6%) 
33 (10.1%) 
107(16.5%) 
 
56 (100%) 
327(100%) 
649(100%) 
 
0.000207 
 
0.0012 
Pleomorphism                             
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
13  (86.7%) 
282(73.2%) 
421(67.0%) 
 
0  (0%) 
74(19.2%) 
72(11.5%) 
 
0  (0%) 
22 (5.7%) 
120(19.1%) 
 
2  (13.3%) 
7  (1.8%) 
15 (2.4%) 
 
3.5x10-10 
 
p<0.0001 
Tumour Type                
IDC-NST 
Tubular  
Medullary  
ILC 
Others 
Mixed NST& Lobular special 
type 
 
418 (66.5%) 
144(70.6%) 
18   (56.3%) 
96   (85.7%) 
9     (75%) 
38   (65.5%) 
 
82 (13%) 
40  (19.6%) 
1    (3.1%) 
13  (11.6%) 
3    (25%) 
16  (27.6%) 
 
113 (18%) 
11   (5.4%) 
12   (37.5%) 
3     (2.7%) 
0     (0%) 
3     (5.2%) 
 
16  (2.5%) 
9    (4.4%) 
1    (3.1%) 
0    (0 %) 
1    (1.7%) 
27  (2.6%) 
 
6.4x10-10 
 
p <0.0001 
HER-2 
Negative 
Positive 
 
626(69.0) 
95 (66.4) 
 
140 (15.4) 
16 (11.2) 
 
116 (12.8) 
30 (21.0) 
 
25 (2.8) 
2 (1.4) 
 
0.037 
 
0.1418 
ER               
Negative 
Positive 
 
150 (55.8%) 
574 (74.1%) 
 
28   (10.4%) 
124 (16.0%) 
 
76 (28.3%) 
66 (8.5%) 
 
15 (5.6%) 
11 (1.4%) 
 
2.6x10-18 
 
p<0.0001 
PR                                   
Negative 
Positive 
 
260 (61.2%) 
464 (74.1%) 
 
 
47 (11.1%) 
108(17.3%) 
 
101 (23.8%) 
44   (7.0%) 
 
17  (4.0%) 
10  (1.6%) 
 
4.6x10-15 
 
p<0.0001 
Supplementary Table S6: Clinicopathological significance of XRCC1 expression in CD8 positive and CD8 negative breast 
cancers  
 
  
 
 
 
CD8 and XRCC1 expression 
 
 
 
P- value 
 
 
 
*P -Value 
(Adjusted) XRCC1+ 
/CD8+ 
 
XRCC1+ 
/CD8- 
 
XRCC1- 
/CD8+ 
 
XRCC1- 
/CD8- 
 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
61  (71.8%) 
346 (76.8%) 
254(67.6%) 
12   (63.2%) 
 
11(12.9%) 
90(17.6%) 
52(13.8%) 
3  (15.8%) 
 
11(12.9%) 
52(10.2%) 
62(16.5%) 
3   (15.8%) 
 
2 (2.4%) 
22(4.3%) 
8  (2.1%) 
1  (5.3%) 
 
 
0.161 
 
 
0.1756 
 
 
 
Tumour Stage                                 
1 
2 
3 
 
393(66.3%) 
209(67.9%) 
71  (78.0%) 
 
106(17.9%) 
45  (14.6%) 
7    (7.7%) 
 
67(11.3%) 
49(15.9%) 
11(12.1%) 
 
27(4.6%) 
5  (1.6%) 
2  (2.2%) 
 
0.013 
 
 
0.0173 
 
 
Tumour Grade                              
 G1 
 G2 
 G3 
 
97    (66%) 
238(75.8%) 
71    (78%) 
 
 
33(22.4%) 
51 (16.2%) 
73 (13.8%) 
 
12(8.2%) 
17(5.4%) 
99(18.7%) 
 
5  (3.4%) 
8  (2.5%) 
20(3.8%) 
 
3.5x10-7 
 
p<0.0001 
NPI                              
 ≤ 3.4 
 >3.4 
 
196(71.3%) 
442(65.7%) 
 
54(19.6%) 
99(14.7%) 
 
16(5.8%) 
108(16%) 
 
9 (3.3%) 
24(3.6%) 
 
0.000214 
 
0.0004 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
231(74.3%) 
128(70.3%) 
301 (64%) 
 
53 (17%) 
28(15.4%) 
64(13.6%) 
 
20 (6.4%) 
18 (9.9%) 
89 (18.9%) 
 
7(2.3%) 
8(4.4%) 
16(3.4%) 
 
0.000036 
 
0.0001 
 
Tubule Formation                          
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
26(56.5%) 
211(68.7%) 
423(69.3%) 
 
16 (34.8%) 
53(17.3%) 
76 (12.5%) 
 
 
3  (6.5%) 
31(10.1%) 
93 (15.2%) 
 
1(2.2%) 
12(3.9%) 
18(3.0%) 
 
 
 
0.001 
 
 
0.0015 
 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
14  (87.5%) 
254(71.1%) 
389(66.5%) 
 
2   (12.5%) 
70 (19.6%) 
143(14.9%) 
 
0  (0) 
23(6.4%) 
104(17.8) 
 
0  (0) 
10(2.8%) 
21(3.6%) 
 
 
0.000005 
 
 
p <0.0001 
Tumour Type                
IDC-NST 
Tubular  
Medullary  
ILC 
Others 
Mixed NST & Lobular/special 
type 
 
408(67.4%) 
120(64.5%) 
18(64.3%) 
81(82.7%) 
6  (54.5%) 
31(62%) 
 
86(14.2%) 
42(22.6%) 
0   (0) 
10(10.2%) 
3  (27.3%) 
12(24%) 
 
93(15.4%) 
17(9.1%) 
8  (28.6%) 
5  (5.1%) 
1  (9.1%) 
4  (8%) 
 
18(3.0%) 
7 (3.8%) 
2 (7.1%) 
2 (2.0%) 
1 (9.1%) 
3 (6%) 
 
 
0.000485 
 
 
0.0008 
 
Her2 overexpression                     
No 
Yes 
 
571(67.6%) 
92  (67.2%) 
 
139(16.4%) 
19 (13.9%) 
 
107(12.7) 
22 (16.1%) 
 
28(3.3%) 
4  (2.9%) 
 
0.663 
 
7.9560 
 
ER               
Negative 
Positive 
 
148(59.0%) 
512(71.2%) 
 
29(11.6%) 
124(17.2%) 
 
60(23.9%) 
66(9.2%) 
 
14(5.6%) 
17(2.4%) 
 
9.3x10-7 
 
p <0.0001 
PR                                   
Negative 
Positive 
 
240(60.8%) 
401(71.7%) 
 
56(14.2%) 
100(17.9%) 
 
80(20.3%) 
45(8.1%) 
 
19(4.8%) 
13(2.3%) 
 
5.4x10-8 
 
p <0.0001 
Supplementary Table S7: Clinicopathological significance of ATM expression in FOXP3 positive and FOXP3negative breast 
cancer  
  
 
 
 
FOXP3 and ATM expression 
 
 
 
P- value 
 
 
 
*P -Value 
(Adjusted) ATM+ 
/ FOXP3+ 
 
ATM+ 
/ FOXP3- 
 
ATM- 
/ FOXP3+ 
 
ATM- 
/ FOXP3- 
 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
19 (20%) 
145 (30.7%) 
81  (27.7%) 
2  (15.4%) 
 
25   (26.3%) 
103 (21.8%) 
41   (14%) 
2   (15.4%) 
 
31 (32.6 
154( 32.6 
113 (38.7 
6 (46.2 
 
20 (21.1 
71 (15 
57(19.5 
3  (23.1 
 
 
0.036 
 
 
0.3960 
 
Tumour Stage                              
1 
2 
3 
 
157 (28.4%) 
71 (28.2%) 
19 (27.9%) 
 
122 (22.1%) 
42   (16.7%) 
8    (11.8%) 
 
185 (33.5%) 
87   (34.5%) 
32   (47.1%) 
 
 
89 (16.1%) 
52 (20.6%) 
9   (13.2%) 
 
 
0.092 
 
 
0.5060 
 
Tumour Grade                            
 G1 
 G2 
 G3 
 
40  (28%) 
66  (23.1%) 
141(31.7%) 
 
56 (39.2%) 
73 (25.5%) 
43 (9.7%) 
 
26  (18.2%) 
74  (25.9%) 
204 (45.8%) 
 
21 (14.7%) 
73 (25.5%) 
57 (12.8%) 
 
1.7X 10-21 
 
<0.0001 
NPI                              
 ≤ 3.4 
 >3.4 
 
69 (25.9%) 
170(29.6%) 
 
84 (31.6%) 
82 (14.3%) 
 
64   (24.1%) 
226 (39.3%) 
 
49 (18.4%) 
97 (16.9%) 
 
6.5 X10-9 
 
<0.0001 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
72   (24.2%) 
44   (27.2%) 
126 (31.4%) 
 
99 (33.3%) 
32 (19.8%) 
39 (9.7%) 
 
66 (22.2%) 
53 (32.7%) 
183(45.6%) 
 
60 (20.2%) 
33 (20.4%) 
53 (13.2%) 
 
4.1x10-16 
 
<0.0001 
Tubule Formation                       
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
10  (20.4%) 
82  (29.3%) 
150 (28.2%) 
 
16 (32.7%) 
80 (28.6%) 
74  (13.9%) 
 
14 (28.6%) 
70  (25%) 
218(41.1%) 
 
 
9 (18.4%) 
48(17.1%) 
89(16.8%) 
 
5.5x10-7 
 
<0.0001 
Pleomorphism                             
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
6   (30%) 
83 (25.2%) 
151(29.7%) 
 
7 (35%) 
97(29.5%) 
66 (13%) 
 
6    (30%) 
74  (22.5%) 
222 (43.7%) 
 
1 (5%) 
75 (22.8%) 
69 (13.6%) 
 
7.8x10-3 
 
<0.0001 
Tumour Type                
IDC-NST 
Tubular  
Medullary 
ILC 
Others 
Mixed NST &lobular/ special 
type               
 
 
158 (30.6%) 
51   (28%) 
11   (36.7%) 
10  (13%) 
1    (12.5%) 
12   (24.5%) 
 
72 (13.9%) 
59 (32.4%) 
1   (3.3%) 
24 (31.4%) 
2  (25%) 
14 (28.6%) 
 
212 (41%) 
41  (22.5%) 
18  (60%) 
17 (22.1%) 
2   (25%) 
11 (22.4%) 
 
75(14.5%) 
31(17%) 
0  (0%) 
26(33.8%) 
3  (37.5%) 
12 (24.5%) 
 
4.4x10-13 
 
<0.0001 
HER-2 overexpression                
No 
Yes 
 
198 (26.8%) 
48   (39.8%) 
 
165(22.2%) 
4    (3.3%) 
 
244 (32.9%) 
57  (46.7%) 
 
135(18.2%) 
13  (10.7%) 
 
1.6x10-7 
 
<0.0001 
ER               
Negative 
Positive 
 
76  (32.2%) 
168(26.8%) 
 
18  (7.6%) 
153(24.4%) 
 
117 (49.6%) 
181 (28.9%) 
 
25 (10.6%) 
124(19.8%) 
 
4.7x10-12 
 
<0.0001 
PR                                   
Negative 
Positive 
 
99 (28.7%) 
140(27.9%) 
 
41  (11.9%) 
123(24.6%) 
 
156 (45.2%) 
141 (28.1%) 
 
49 (14.2%) 
97 (19.4%) 
 
4.4x10-8 
 
<0.0001 
Supplementary Table S8: Clinicopathological significance of BRCA1 expression in FOXP3 positive and FOXP3negative breast 
cancer  
  
 
 
 
FOXP3 and ATM expression 
 
 
 
P- value 
 
 
 
*P -Value 
(Adjusted) BRCA1+ 
/ FOXP3+ 
 
BRCA1+ 
/ FOXP3- 
 
BRCA1- 
/ FOXP3+ 
 
BRCA1- 
/ FOXP3- 
 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
60 (51.3%) 
308(54.4%) 
230(54.1%) 
8   (38.1%) 
 
 
48  (41%) 
177(31.3%) 
118 (27.8%) 
6     (28.6%) 
 
5 (4.3%) 
58(10.2%) 
60(14.1%) 
6  (28.6%) 
 
4 (3.4%) 
23(4.1%) 
17(4%) 
1  (4.8%) 
 
 
0.015 
 
 
0.0165 
 
Tumour Stage                              
1 
2 
3 
 
354 (51.5%) 
196 (56.5%) 
56   (58.3%) 
 
217 (31.6%) 
109 (109%) 
24   (25%) 
 
86 (12.5%) 
31  (8.9%) 
12  (12.5%) 
 
30 (4.4%) 
11 (3.2%) 
4   (4.2%) 
 
 
 
0.397 
 
 
4.3670 
 
Tumour Grade                            
 G1 
 G2 
 G3 
 
81  (44.3%) 
176 (47.4%) 
349 (60.6%) 
 
83 (45.4%) 
170(45.8%) 
97  (16.8%)
 
5   (2.7%) 
15  (4%) 
109 (18.9%)
 
14 (7.7%) 
10 (2.7%) 
21 (3.6%)
 
2.0X10-30 
 
<0.0001 
NPI                              
 ≤ 3.4 
 >3.4 
 
161 (48.3%) 
416 (55.7%) 
 
143 (42.9%) 
192 (25.7%) 
 
13 (3.9%) 
112 (15%) 
 
16 (4.8%) 
27 (3.6%) 
 
9.3 X10-11 
 
<0.0001 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
171 (45.1%) 
108 (51.9%) 
312 (60.7%) 
 
183(48.3%) 
76 (36.5%) 
84 (16.3%) 
 
11 (2.9%) 
17 (8.2%) 
97 (18.9%) 
 
14 (3.7%) 
7   (3.4%) 
21 (4.1%) 
 
9.5X10-27 
 
<0.0001 
Tubule Formation                       
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
26 (44.1%) 
178(49.7%) 
387(56.6%) 
 
26 (44.1%) 
139(38.8%) 
178(26%) 
 
0   (0%) 
25  (7%) 
100(14.6%) 
 
7 (11.9%) 
16(4.5%) 
19(2.8%) 
 
4.0x10-9 
 
<0.0001 
Pleomorphism                             
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
8   (42.1%) 
204(47.8%) 
376(57.8%) 
 
9   (47.4%) 
191(44.7%) 
142(21.8%) 
 
1  (5.3%) 
12 (2.8%) 
112(17.2%) 
 
1 (5.3%) 
20(4.7%) 
21(3.2%) 
 
3.3x10-19 
 
<0.0001 
Tumour Type                
IDC-NST 
Tubular  
Medullary 
ILC 
Others 
Mixed NST &lobular/ special 
type               
 
 
383(58.4%) 
107(47.6%) 
19  (59.4%) 
56  (44.4%) 
6   (54.5%) 
29 (43.3%) 
 
 
145 (22.1%0 
96  (42.7%) 
0    (0%) 
68 (54%) 
5   (45.5%) 
33  (49.3%) 
 
102 (15.5%) 
9     (4%) 
13   (40.6%) 
1     (0.8%) 
0     (0%) 
1    (1.5%) 
 
26 (4%) 
13 (5.8%) 
0   (0%) 
1   (0.8%) 
0   (0%) 
4   (6%) 
 
1.5x10-23 
 
<0.0001 
HER-2 overexpression                
No 
Yes 
 
511(52.3%) 
93  (64.1%) 
 
323(33.1%) 
21  (14.5%) 
 
101(10.3%) 
28 (19.3%) 
 
42 (4.3%) 
3   (2.1%) 
 
0.000004 
 
<0.0001 
ER               
Negative 
Positive 
 
163 (58%) 
431 (52%) 
 
29 (10.3%) 
318(38.4%) 
 
72 (25.6%) 
53 (6.4%) 
 
17 (6%) 
27 (3.3%) 
 
2.1x10-27 
 
<0.0001 
PR                                   
Negative 
Positive 
 
239 (54.7%) 
363 (53.5%) 
 
 
85 (19.5%) 
256(37.8%) 
 
90 (20.6%) 
37 (5.5%) 
 
23 (5.3%) 
22 (3.2%) 
 
2.2x10-18 
 
<0.0001 
Supplementary Table S9: Clinicopathological significance of XRCC1 expression in FOXP3 positive and FOXP3negative breast 
cancer.  
 
 
 
 
 
FOXP3 and ATM expression 
 
 
 
P- value 
 
 
 
*P -Value 
(Adjusted) XRCC1+ 
/ FOXP3+ 
 
XRCC1+ 
/ FOXP3- 
 
XRCC1- 
/ FOXP3+ 
 
XRCC1- 
/ FOXP3- 
 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
45 (45.5%) 
293(53.5%) 
206(52.3%) 
10  (52.6%) 
 
39 (39.4%) 
176(32.1%) 
111(28.2%) 
5    (26.3%) 
 
9  (9.1%) 
52 (9.5%) 
55 (14%) 
4   (21.1%) 
 
6  (6.1%) 
28(5.1%) 
22 (5.6%) 
0   (0%) 
 
0.219 
 
2.4090 
 
Tumour Stage                              
1 
2 
3 
 
340 (52.5%) 
158 (49.1%) 
57   (60.6%) 
 
204 (31.5%) 
107 (33.2%) 
22   (23.4%) 
 
63  (9.7%) 
43  (13.4%) 
14  (14.9%) 
 
41 (6.3%) 
14 (4.3%) 
1   (1.1%) 
 
0.044 
 
0.0484 
 
Tumour Grade                            
 G1 
 G2 
 G3 
 
74 (41.8%) 
157(45.8%) 
323 (59.6%) 
 
81 (45.8%) 
158(46.1%) 
93  (17.2%) 
 
8  (4.5%) 
9    (2.6%) 
103 (19%) 
 
14 (7.9%) 
19 (5.5%) 
23 (4.2%) 
 
1.1 X10-28 
 
<0.0001 
NPI                              
 ≤ 3.4 
 >3.4 
 
150 (47.8%) 
379 (53.7%) 
 
134 (42.7%) 
187 (26.5%) 
 
 
10 (3.2%) 
104(14.7%) 
 
20 (6.4%) 
36 (5.1%) 
5.3X10-10 
 
<0.0001 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
154 (43.1%) 
101(52.3%) 
282(58.8%) 
 
170(47.6%) 
63 (32.6%) 
87 (18.1%) 
 
14 (3.9%) 
14 (7.3%) 
92 (19.2%) 
 
19 (5.3%) 
15 (7.8%) 
19 (4%) 
 
1.2x10-22 
 
0.0001 
Tubule Formation                       
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
22 (43.1%) 
168(48.3%) 
347(55%) 
 
22 (43.1%) 
136(39.1%) 
162(25.7%) 
 
2 (3.9%) 
19(5.5%) 
99(15.7%) 
 
5 (9.8%) 
25(7.2%) 
23(3.6%) 
 
7.8x10-9 
 
<0.0001 
Pleomorphism                             
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
10 (41.7%) 
177(44.5%) 
346(57.4%) 
 
 
11 (45.8%) 
183(46%) 
125(20.7%) 
 
1 (4.2%) 
15(3.8%) 
104(17.2%) 
 
2 (8.3%) 
23(5.8%) 
28(4.6%) 
 
5.2x10-19 
 
<0.0001 
Tumour Type                
IDC-NST 
Tubular  
Medullary 
ILC 
Others 
Mixed NST &lobular/ special 
type               
 
 
370 (59.2%) 
92   (43.2%) 
17   (60.7%) 
38   (34.2%) 
3     (23.1%) 
26   (42.6%) 
 
137 (21.9%) 
92   (43.2%) 
1     (3.6%) 
64   (57.7%) 
8     (61.5%) 
26   (42.6%) 
 
92 (14.7%) 
11 (5.2%) 
10 (35.7%) 
4   (3.6%) 
0   (0%) 
3   (4.9%) 
 
26 (4.2%) 
17 (8%) 
0  (0%) 
5  (4.5%) 
2  (15.4%) 
6  (9.8%) 
 
5.1x10-21 
 
<0.0001 
HER-2 overexpression                
No 
Yes 
 
458 (50.2%) 
93  (66.9%) 
 
308 (33.7%) 
18   (12.9%) 
 
100 (11%) 
21   (15.1%) 
 
47 (5.1%) 
7   (5%) 
 
0.000015 
 
<0.0001 
ER               
Negative 
Positive 
 
151 (58.8%) 
390 (50.1%) 
 
27 (10.5%) 
298 (38.3%) 
 
61 (23.7%) 
55 (7.1%) 
 
18 (7%) 
35 (4.5%) 
 
1.19x10-21 
 
<0.0001 
PR                                   
Negative 
Positive 
 
216 (53.5%) 
316 (52%) 
 
83 (20.5%) 
229(37.7%) 
 
80 (19.8%) 
35 (5.8%) 
 
25 (6.2%) 
28 (4.6%) 
 
2.4x10-14 
 
<0.0001 
SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure S1: Prognostic significance of ATM, BRCA1 and XRCC1 in breast cancers 
negative for CD8+ TILs. Kaplan-Meier survival curves are shown here. 
Supplementary Figure S2: Prognostic significance of polβ (A &B), ERCC1 (C&D), RECQL4 (E&F), 
RECQL5 (G &H), BLM (I & J), PARP1 (K & L), FEN1 ( M & N), TOPO2A (O & P), Ku70/Ku80 (Q & R), 
Chk2 (S & T), WRN (U & V) and DNA-PKcs (W & X)  in CD8+ TILs positive and CD8+ TILs negative 
breast cancers respectively. Kaplan-Meier survival curves are shown here. 
Supplementary Figure S3: Correlation between CD8 counts and ATM (A), BRCA1 (B) and XRCC1 (C).  
Supplementary Figure S4: Prognostic significance of ATM, BRCA1 and XRCC1 in FOXP3+ or FOXP3 
negative breast cancers. Kaplan-Meier survival curves are shown here. 
Supplementary Figure S5: Prognostic significance of ATM, BRCA1 in PD-L1+ (tumour cells), PD-L1+ 
(TILs) or PD-1+ (TILs) is shown here. Kaplan-Meier survival curves are shown here. 
Supplementary Figure S6: Prognostic significance of ATM, BRCA1 and XRCC1 in PD-L1 negative 
(tumour cells), PD-L1 negative (TILs) and PD-1 negative (TILs) breast cancers. Kaplan-Meier survival 
curves are shown here. 
Supplementary Figure S7: Prognostic significance of CD8+ TILs in ER+ breast cancer [whole cohort (A), 
received no endocrine therapy (B) and received endocrine therapy (C)] is shown here.  
Supplementary Figure S8: Prognostic significance of  BRCA1 (A), XRCC1 (B) or ATM (C) in CD8+ 
TILs positive ER+ breast cancer. Kaplan-Meier survival curves are shown here. 
Supplementary Figure S9: Prognostic significance of XRCC1 in CD8+/CD8- (A), PD-1+/PD-1- (B), 
FOXP3+/FOXP3- (C) and PD-L1+/PD-L1- (D) ER+ breast cancer that received no endocrine therapy.  
Supplementary Figure S10: A. Prognostic significance of XRCC1 in PD-1+/PD-1- HER2 + breast cancers. 
B. Prognostic significance of BRCA1 in FOXP3+/FOXP3- HER2 + breast cancers.  Kaplan-Meier survival 
curves are shown here. 
Supplementary Figure S11: Prognostic significance of CD8+ TILs in ER- breast cancer [whole cohort (A), 
received no chemotherapy (B) and received chemotherapy (C)] is shown here. Kaplan-Meier survival curves 
are shown here. 
Supplementary Figure S12:.Prognostic significance of BRCA1 in PD-L1+/PD-L1- ER- breast cancers that 
received no chemotherapy. Kaplan-Meier survival curves are shown here. 
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